Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms release positive survival data from pivotal trial of Tarceva in combination with Lilly’s Gemzar. Investigators believe pancreatic cancer is a “logical place to look” for expanded use of EGFR inhibitors like Tarceva.